| Autor: |
Panagiotis A. Konstantinopoulos, Alexandre André B. A. da Costa, Doga Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L. Kolin, Elise C. Kohn, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Nabihah Tayob, Madeline Polak, Dipanjan Chowdhury, Ursula A. Matulonis, Anniina Färkkilä, Alan D. D’Andrea, Geoffrey I. Shapiro |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2041-1723 |
| DOI: |
10.1038/s41467-021-25904-w |
| Popis: |
A randomized phase 2 study recently showed that the addition of ATR inhibitor berzosertib to gemcitabine improved PFS compared to gemcitabine alone in patients with ovarian cancer. In this preplanned exploratory study, the authors demonstrate that a genomic biomarker of replication-stress is associated with outcome to gemcitabine alone and may predict which patients benefit from addition of the ATR inhibitor berzosertib. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink